{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T21:23:52Z","timestamp":1772054632415,"version":"3.50.1"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T00:00:00Z","timestamp":1761264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Gene Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1038\/s41417-025-00973-x","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T06:48:40Z","timestamp":1761288520000},"page":"65-75","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Using RNA-seq for detecting MRD in multiple myeloma: high sensitivity and prognostic value"],"prefix":"10.1038","volume":"33","author":[{"given":"Yuyue","family":"Ren","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiancheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lianjie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanming","family":"Xue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiwei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liyan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yaoyao","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaomin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Biqing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dandan","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoli","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0547-5721","authenticated-orcid":false,"given":"Hongxing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2344-1496","authenticated-orcid":false,"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,24]]},"reference":[{"key":"973_CR1","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1002\/ajh.25117","volume":"93","author":"SV Rajkumar","year":"2018","unstructured":"Rajkumar SV. Multiple myeloma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93:1091\u2013110.","journal-title":"Am J Hematol"},{"key":"973_CR2","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538\u201348.","journal-title":"Lancet Oncol"},{"key":"973_CR3","unstructured":"Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, et al. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute. Bethesda, MD, https:\/\/seer.cancer.gov\/csr\/1975_2017\/, based on November 2019 SEER data submission, posted to the SEER web site, April 2020."},{"key":"973_CR4","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, et al. Global burden of multiple myeloma. JAMA Oncol. 2018;4:1221.","journal-title":"JAMA Oncol"},{"key":"973_CR5","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"},{"key":"973_CR6","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-020-00359-2","volume":"10","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV, Kumar S. Multiple myeloma current treatment algorithms. Blood Cancer J. 2020;10:94","journal-title":"Blood Cancer J"},{"key":"973_CR7","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.3390\/cancers14051310","volume":"14","author":"R Colmenares","year":"2022","unstructured":"Colmenares R, \u00c1lvarez N, Barrio S, Mart\u00ednez-L\u00f3pez J, Ayala R. The minimal residual disease using liquid biopsies in hematological malignancies. Cancers. 2022;14:1310.","journal-title":"Cancers"},{"key":"973_CR8","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1182\/blood-2015-03-580027","volume":"125","author":"JJ van Dongen","year":"2015","unstructured":"van Dongen JJ, van der Velden VH, Br\u00fcggemann M, Orfao A. Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood. 2015;125:3996\u20134009.","journal-title":"Blood"},{"key":"973_CR9","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016;17:e328\u201346.","journal-title":"Lancet Oncol"},{"key":"973_CR10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma. JAMA Oncol. 2017;3:28.","journal-title":"JAMA Oncol"},{"key":"973_CR11","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB. et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"973_CR12","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1186\/s13045-020-00911-4","volume":"13","author":"L Burgos","year":"2020","unstructured":"Burgos L, Puig N, Cedena MT, Mateos MV, Lahuerta JJ, Paiva B. et al. Measurable residual disease in multiple myeloma: ready for clinical practice?. J Hematol. Oncol. 2020;13:82","journal-title":"J Hematol. Oncol"},{"key":"973_CR13","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"MV Mateos","year":"2018","unstructured":"Mateos MV, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, et al. Daratumumab plus bortezomib, melphalan, and prednisone for untreated myeloma. N Engl J Med. 2018;378:518\u201328.","journal-title":"N Engl J Med"},{"key":"973_CR14","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1182\/blood.2021011101","volume":"139","author":"M Cavo","year":"2022","unstructured":"Cavo M, San-Miguel J, Usmani SZ, Weisel K, Dimopoulos MA, Avet-Loiseau H, et al. Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA. Blood. 2022;139:835\u201344.","journal-title":"Blood"},{"key":"973_CR15","doi-asserted-by":"crossref","first-page":"932852","DOI":"10.3389\/fonc.2022.932852","volume":"12","author":"V Ferla","year":"2022","unstructured":"Ferla V, Antonini E, Perini T, Farina F, Masottini S, Malato S, et al. Minimal residual disease detection by next-generation sequencing in multiple myeloma: promise and challenges for response-adapted therapy. Front Oncol. 2022;12:932852.","journal-title":"Front Oncol"},{"key":"973_CR16","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/imr.12659","volume":"284","author":"D Dunn-Walters","year":"2018","unstructured":"Dunn-Walters D, Townsend C, Sinclair E, Stewart A. Immunoglobulin gene analysis as a tool for investigating human immune responses. Immunol Rev. 2018;284:132\u201347.","journal-title":"Immunol Rev"},{"key":"973_CR17","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1200\/EDBK_175175","volume":"37","author":"M Bustoros","year":"2017","unstructured":"Bustoros M, Mouhieddine TH, Detappe A, Ghobrial IM. Established and novel prognostic biomarkers in multiple myeloma. Am Soc Clin Oncol Educ book. 2017;37:548.","journal-title":"Am Soc Clin Oncol Educ book"},{"key":"973_CR18","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.27249","volume":"99","author":"X Chen","year":"2024","unstructured":"Chen X, Yuan L, Zhang Y, Wang F, Ma X, Fang J, et al. Advances towards genome-based acute myeloid leukemia classification: a comparative analysis of WHO-HAEM4R, WHO-HAEM5, and international consensus classification. Am J Hematol. 2024;99:824\u201335.","journal-title":"Am J Hematol"},{"key":"973_CR19","volume":"11","author":"X Chen","year":"2021","unstructured":"Chen X, Wang F, Zhang Y, Ma X, Cao P, Yuan L, et al. Fusion gene map of acute leukemia revealed by transcriptome sequencing of a consecutive cohort of 1000 cases in a single center. Blood Cancer J. 2021;11:112.","journal-title":"Blood Cancer J"},{"key":"973_CR20","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1002\/mc.23514","volume":"62","author":"X Zhou","year":"2023","unstructured":"Zhou X, Nie D, Zhang Y, Liu Z, Zhao Y, Zhang J, et al. DNTT activation, TdT-aided gene length mutation, and better prognosis in ATG-based regimen allo-HSCT in AML. Mol Carcinog. 2023;62:665\u201375.","journal-title":"Mol Carcinog"},{"key":"973_CR21","doi-asserted-by":"crossref","first-page":"15691.","DOI":"10.3390\/ijms232415691","volume":"23","author":"A Matera","year":"2022","unstructured":"Matera A, Marella A, Maeda A, Da Vi\u00e0 MC, Lazzaroni F, Fabris S. et al. Single-cell RNA sequencing for the detection of clonotypic V(D)J rearrangements in multiple myeloma. Int J Mol Sci. 2022;23:15691.","journal-title":"Int J Mol Sci"},{"key":"973_CR22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s12672-024-00938-w","volume":"15","author":"M Zhou","year":"2024","unstructured":"Zhou M, Chen Y, Gong Y, Zhu M, Cen J, Pan J, et al. Evaluation of next-generation sequencing versus next-generation flow cytometry for minimal-residual-disease detection in Chinese patients with multiple myeloma. Discov Oncol. 2024;15:78.","journal-title":"Discov Oncol"},{"key":"973_CR23","doi-asserted-by":"crossref","first-page":"449","DOI":"10.3389\/fonc.2019.00449","volume":"9","author":"Q Yao","year":"2019","unstructured":"Yao Q, Bai Y, Orfao A, Chim CS. Standardized minimal residual disease detection by next-generation sequencing in multiple myeloma. Front Oncol. 2019;9:449.","journal-title":"Front Oncol"},{"key":"973_CR24","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.tig.2013.05.010","volume":"29","author":"E Eisenberg","year":"2013","unstructured":"Eisenberg E, Levanon EY. Human housekeeping genes, revisited. Trends Genet. 2013;29:569\u201374.","journal-title":"Trends Genet"},{"key":"973_CR25","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/S0140-6736(21)00135-5","volume":"397","author":"N van de Donk","year":"2021","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021;397:410\u201327.","journal-title":"Lancet"},{"key":"973_CR26","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1038\/leu.2017.138","volume":"31","author":"SK Kumar","year":"2017","unstructured":"Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, et al. Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study. Leukemia. 2017;31:2443\u20138.","journal-title":"Leukemia"},{"key":"973_CR27","doi-asserted-by":"crossref","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"973_CR28","volume":"14","author":"H Chen","year":"2023","unstructured":"Chen H, Gu M, Liang J, Song H, Zhang J, Xu W, et al. Minimal residual disease detection by next-generation sequencing of different immunoglobulin gene rearrangements in pediatric B-ALL. Nat Commun. 2023;14:7468.","journal-title":"Nat Commun"},{"key":"973_CR29","doi-asserted-by":"crossref","first-page":"101226.","DOI":"10.1016\/j.blre.2024.101226","volume":"68","author":"Q Shen","year":"2024","unstructured":"Shen Q, Gong X, Feng Y, Hu Y, Wang T, Yan W. et al. Measurable residual disease (MRD)-testing in haematological cancers: a giant leap forward or sideways?. Blood Rev. 2024;68:101226.","journal-title":"Blood Rev"},{"key":"973_CR30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.cca.2011.03.007","volume":"412","author":"T Nakano","year":"2011","unstructured":"Nakano T, Matsui M, Inoue I, Awata T, Katayama S, Murakoshi T. Free immunoglobulin light chain: its biology and implications in diseases. Clin Chim Acta. 2011;412:843\u20139.","journal-title":"Clin Chim Acta"},{"key":"973_CR31","doi-asserted-by":"crossref","first-page":"9531.","DOI":"10.3390\/ijms24119531","volume":"24","author":"M Gudowska-Sawczuk","year":"2023","unstructured":"Gudowska-Sawczuk M, Mroczko B. Free light chains kappa and lambda as new biomarkers of selected diseases. Int J Mol Sci. 2023;24:9531.","journal-title":"Int J Mol Sci"},{"key":"973_CR32","doi-asserted-by":"crossref","first-page":"1123029","DOI":"10.3389\/fonc.2023.1123029","volume":"13","author":"G Gkoliou","year":"2023","unstructured":"Gkoliou G, Agathangelidis A, Karakatsoulis G, Lalayanni C, Papalexandri A, Medina A, et al. Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories. Front Oncol. 2023;13:1123029.","journal-title":"Front Oncol"},{"key":"973_CR33","volume":"10","author":"A Medina","year":"2020","unstructured":"Medina A, Jim\u00e9nez C, Sarasquete ME, Gonz\u00e1lez M, Chill\u00f3n MC, Balanzategui A, et al. Molecular profiling of immunoglobulin heavy-chain gene rearrangements unveils new potential prognostic markers for multiple myeloma patients. Blood Cancer J. 2020;10:14.","journal-title":"Blood Cancer J"},{"key":"973_CR34","doi-asserted-by":"crossref","first-page":"e0253541","DOI":"10.1371\/journal.pone.0253541","volume":"16","author":"M Kim","year":"2021","unstructured":"Kim M, Jeon K, Hutt K, Zlotnicki AM, Kim HJ, Lee J, et al. Immunoglobulin gene rearrangement in Koreans with multiple myeloma: clonality assessment and repertoire analysis using next-generation sequencing. PLoS ONE. 2021;16:e0253541.","journal-title":"PLoS ONE"},{"key":"973_CR35","first-page":"781","volume":"91","author":"A Hadzidimitriou","year":"2006","unstructured":"Hadzidimitriou A, Stamatopoulos K, Belessi C, Lalayianni C, Stavroyianni N, Smilevska T, et al. Immunoglobulin genes in multiple myeloma: expressed and non-expressed repertoires, heavy and light chain pairings and somatic mutation patterns in a series of 101 cases. Haematologica. 2006;91:781\u20137.","journal-title":"Haematologica"},{"key":"973_CR36","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1038\/s41568-024-00755-x","volume":"24","author":"DM Cordas Dos Santos","year":"2024","unstructured":"Cordas Dos Santos DM, Toenges R, Bertamini L, Alberge JB, Ghobrial IM. et al. New horizons in our understanding of precursor multiple myeloma and early interception. Nat Rev Cancer. 2024;24:867\u201386.","journal-title":"Nat Rev Cancer"},{"key":"973_CR37","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.","journal-title":"Nat Commun"},{"key":"973_CR38","first-page":"501","volume":"36","author":"S Deng","year":"2015","unstructured":"Deng S, Xu Y, An G, Sui W, Li Z, Zou D, et al. Clinical analysis of multiple myeloma patients with bone-related extramedullary disease: a longitudinal study on 834 consecutive patients in a single center of China]. Zhonghua Xue Ye Xue Za Zhi. 2015;36:501\u20136.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"973_CR39","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1200\/JCO.21.01365","volume":"40","author":"JJ Garc\u00e9s","year":"2022","unstructured":"Garc\u00e9s JJ, Cedena MT, Puig N, Burgos L, Perez JJ, Cordon L. et al. Circulating tumor cells for the staging of patients with newly diagnosed transplant-eligible multiple myeloma. J Clin Oncol. 2022;40:3151\u201361.","journal-title":"J Clin Oncol"},{"key":"973_CR40","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.21.01393","volume":"40","author":"L Bertamini","year":"2022","unstructured":"Bertamini L, Oliva S, Rota-Scalabrini D, Paris L, Mor\u00e8 S, Corradini P, et al. High levels of circulating tumor plasma cells as a key hallmark of aggressive disease in transplant-eligible patients with newly diagnosed multiple myeloma. J Clin Oncol. 2022;40:3120\u201331.","journal-title":"J Clin Oncol"},{"key":"973_CR41","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1200\/JCO.22.01226","volume":"41","author":"T Jelinek","year":"2023","unstructured":"Jelinek T, Bezdekova R, Zihala D, Sevcikova T, Anilkumar Sithara A, Pospisilova L, et al. More than 2% of circulating tumor plasma cells defines plasma cell leukemia-like multiple myeloma. J Clin Oncol. 2023;41:1383\u201392.","journal-title":"J Clin Oncol"},{"key":"973_CR42","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood. 2019;133:660\u201375.","journal-title":"Blood"},{"key":"973_CR43","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bjh.17118","volume":"193","author":"P Galieni","year":"2021","unstructured":"Galieni P, Travaglini F, Vagnoni D, Ruggieri M, Caraffa P, Bigazzi C, et al. The detection of circulating plasma cells may improve the Revised International Staging System (R-ISS) risk stratification of patients with newly diagnosed multiple myeloma. Br J Haematol. 2021;193:542\u201350.","journal-title":"Br J Haematol"}],"container-title":["Cancer Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00973-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00973-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T23:02:11Z","timestamp":1768172531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41417-025-00973-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,24]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["973"],"URL":"https:\/\/doi.org\/10.1038\/s41417-025-00973-x","relation":{},"ISSN":["0929-1903","1476-5500"],"issn-type":[{"value":"0929-1903","type":"print"},{"value":"1476-5500","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,24]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Ethics Committee of the Second Affiliated Hospital of Harbin Medical University. All patients and healthy donors signed informed consent forms after the study had been thoroughly explained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}